ArticleBritish journal of cancer2024

Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.

Koji Haratani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.